Journal:

Article Title: Riboflavin Production in Lactococcus lactis : Potential for In Situ Production of Vitamin-Enriched Foods

doi: 10.1128/AEM.70.10.5769-5777.2004

Figure Lengend Snippet: Comparative analysis of riboflavin biosynthesis genes among various LAB strains and B. subtilis

Article Snippet: However, it should be noted that at this time some of these genomes are not complete ( http://www.tigr.org ; http://www.jgi.doe.gov ). table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Strain c RFN element % Homology to L. lactis NZ9000 a Source b ribG ribB ribA ribH ribC Lactococcus lactis subsp. cremoris SK11 1 + 95 98 96 98 99 JGI Lactococcus lactis subsp. lactis IL1403 2 + 72 74 81 82 94 NCBI Streptococcus pneumoniae TIGR4 2 + 52 58 57 69 47 TIGR Streptococcus pneumoniae R6 2 + 52 58 57 69 47 TIGR Streptococcus agalactiae 2603V/R 2 + 47 50 59 60 48 NGBI Leuconostoc mesenteroides 1 + 39 37 42 47 36 JGI Pediococcus pentosaceus ATCC 25745 1 + 36 46 50 49 39 JGI Lactobacillus brevis ATCC 367 1 + 35 40 48 42 39 JGI Lactobacillus plantarum WCFS1 2 - d 47 51 40 NCBI Lactobacillus gasseri ATCC 33323 1 47 37 JGI Lactobacillus casei ATCC 334 1 37 JGI Lactobacillus bulgaricus ATCC BAA365 1 35 JGI Streptococcus thermophilus LMD-9 1 46 JGI Streptococcus pyogenes MGAS8232 2 45 NCBI Streptococcus mitis 1 47 TIGR Oenococcus oeni PSU1 1 35 JGI Enterococcus faecalis V583 2 44 TIGR Bacillus subtilis + 39 50 57 58 36 Open in a separate window a The figures indicate the degree of homology to L. lactis NZ9000 genes. b Sequences were obtained from The Institute for Genomic Research (TIGR), the Joint Genome Institute (JGI), or The National Center for Biotechnology Information (NCBI) website as indicated. c Superscript numbers: 1, uncompleted genomes; 2, completed genomes. d -, 3′ present.

Techniques:

Journal: Molecular cancer therapeutics

Article Title: GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition

doi: 10.1158/1535-7163.MCT-18-0770

Figure Lengend Snippet: (A) A network of downregulated/upregulated proteins in combination group compared to olaparib group was determined using Netwalker analysis. (B) Expression of PI3K/AKT, p-PI3K/p-AKT, PARP, Cleaved PARP, BRCA1, BRCA2, and RAD 51 after treatment. (C) Expression and localization of GnRH-R in BRCA1 mutant (BRCA1m) COV362 and MDA-MB-436 cells and BRCA2 mutant (BRCA2m) KURAMOCHI cells. The fixed cells without permeabilization (left panels) were visualized using confocal microscopy (TCS SP5 MP; Leica Microsystems, Buffalo Grove, IL). The fixed and permeabilized cells (right panels) were visualized using a laser-scanning microscope (Leica). (Scale bar: 50 μM). (D) cell viability of COV362, MDA-MB-436, and KURAMOCHI cells after treatment with EP-100, olaparib, or EP-100 plus olaparib for 72 h. (E) CI values are shown as in Fa-CI plots.

Article Snippet: The primary antibody dilution factors were as follows according to manufacturer’s instructions: anti-GnRH-R (1:1,000, Abcam, Cambridge, UK, Cat: ab183079), RAD 51 (1:10,000, Abcam, Cambridge, UK, Cat: ab133534), phosphorylated PI3K p85 (1:1,000, Cat: 4228s), PI3K (1:1,000, Cat: 4292s), phosphorylated AKT Ser473 (1:1,000, Cat: 9271s), AKT (1:1,000, Cat: 9272s), PARP (1:1,000, Cat: 9532s), BRCA1 (1:1,000, Cat: 9025s) and BRCA2 (1:1,000, Cat: 10741s) (Cell Signaling Technology, Danvers, MA, USA).

Techniques: Expressing, Mutagenesis, Confocal Microscopy, Laser-Scanning Microscopy